Long Focus Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Long Focus Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-35,000	Closed	-$988K	–	120
2022 Q2	$988K	Buy	+35,000	New	+$1.01M	0.1%	78
2022 Q1	–	Sell	-16,824	Closed	-$665K	–	115
2021 Q4	$665K	Buy	+16,824	New	+$527K	0.09%	79

Other funds holding RXDX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Long Focus Capital Management's RXDX Position: Q3 2022 in Review

Long Focus Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q3 2022, closing a stake of 35,000 shares — an estimated $988K sold.

Long Focus Capital Management first reported a position in RXDX in Q4 2021 and held it in 2 quarters. The position peaked at $988K in Q2 2022. 144 funds tracked by Wall St. Rank hold RXDX as of Q3 2022.

Long Focus Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Long Focus Capital Management sold 35,000 Prometheus Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $988K.
Long Focus Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
Long Focus Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $988K in Q2 2022.
144 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q3 2022.

Based on Long Focus Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.